Pamela Wearsch, PhD

Assistant Professor
Department of Pathology
School of Medicine
Director, Department of Pathology MS Programs

Research Information

Research Interests

My current interest in extracellular vesicles and their roles in infection build on my background in relevant areas of cell biology, biochemistry, and immunology. My graduate training (Dept. of Cell Biology, Duke University) was focused on protein transport, folding, and trafficking in the secretory pathway. These projects stimulated my interest in immunology, and I applied my expertise in protein biochemistry to study antigen processing and presentation (HHMI, Dept. of Immunobiology, Yale University). My post-doctoral studies were focused on tapasin, an ER chaperone that facilitates the assembly of MHC class I molecules. I developed in vitro assays to demonstrate the selective, tapasin-mediated loading of high affinity peptides onto MHC class I molecules, determined the crystal structure of tapasin in association with its partner protein ERp57, and identified key residues required for tapasin activity. Taken together, my work elucidated the molecular mechanisms of tapasin function and MHC class I peptide loading.

Research Projects

In a desire to shift my research focus from fundamental immunology to an infection model, I launched a new research program upon my arrival at CWRU to study the immune response to Mycobacterium tuberculosis (Mtb). I have since developed several exciting, new research projects on the role of extracellular vesicles in the Mtb host-pathogen interaction.

A rapidly expanding area of research is the study of extracellular vesicles (EVs) and their clinical applications. Given the progress in recent years, it is now believed that all cell types secrete EVs for the purpose of intercellular communication. Molecular cargo, including proteins, lipids, and RNA, is specifically sorted into vesicles and trafficked via EVs to a recipient cell, thereby regulating the recipient cell function. Although this paradigm was elucidated in studies of exosomes (a type of EV released by mammalian cells), EV-mediated intercellular communication is a universal process that is conserved across kingdoms. Prokaryotes secrete 50–250 nm membrane vesicles in a manner that is regulated by environmental stress and is thought to promote survival. Since many types of host-derived stress are encountered during infection, this implies an important role for membrane vesicle secretion in bacterial virulence. Accordingly, membrane vesicles produced by gram-positive and gram-negative pathogens contain toxins, virulence factors, and other molecules that promote survival in the host. Most studies to date, however, have employed axenic (i.e., broth) culture models for vesicle purification and analysis. It is generally unknown if membrane vesicles are produced during bacterial infection, and, if so, whether they contribute to pathogenesis.

We predict that membrane vesicle secretion is particularly important for the success of Mycobacterium tuberculosis (Mtb), an intracellular pathogen that establishes latent infection and causes TB (tuberculosis). Mtb infects lung macrophages and creates a niche for survival within modified phagosomes. We recently reported the exciting discovery of bacterial membrane vesicle (BMV) production by Mtb within the phagosomes of infected macrophages and the subsequent release of BMVs from infected cells into the extracellular environment. These vesicles contained Mtb lipoproteins and lipoglycans which promote immune evasion and survival. Our findings suggest that 1) BMVs transport Mtb virulence factors to host targets within the infected macrophage, and 2) BMVs may also traffic beyond the site of infection to further promote TB pathogenesis. Our current efforts are aimed at A) determining the mechanisms of BMV biogenesis which are currently unknown, and B) developing in vitro and in vivo models to study the functions of BMVs during Mtb infection. These studies may lead to new strategies for TB diagnosis (serum BMVs as biomarkers) and treatment (drugs that inhibit BMV secretion).


View All Publications

Select Publications